Xingming Deng,Rui Li,Fadio R. Khuri,Taofeek Kunle Owonikoko
申请号：
US14478238
公开号：
US20150065526A1
申请日:
2014.09.05
申请国别(地区):
US
年份:
2015
代理人:
摘要：
This disclosure relates to methods of treating cancer comprising administering an effective amount of a STAT3 inhibitor, prodrugs, or derivatives thereof, in combinations with an EGFR tyrosine kinase inhibitors, prodrugs, or derivatives thereof, to a subject in need thereof. In certain embodiments, the STAT3 inhibitor is niclosamide or salt thereof. In certain embodiments, the EGFR tyrosine kinase inhibitor is erlotinib or salt thereof.
